CART-19 Cells For MRD Positive CD19+ ALL

CART-19 Cells For Patients With Minimal Residual Disease (MRD) Positive CD19+ Acute Lymphoblastic Leukemia

Status

UNKNOWN

Phases

Phase 2Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03027739

Acronym

CCFMPCA

Enrollment

Registered

2017-01-23

Start date

2016-11-30

Completion date

2020-12-31

Last updated

2017-01-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Lymphoblastic Leukemia

Brief summary

CART-19 cells has emerged as a powerful targeted immunotherapy, showing striking responses in highly refractory CD19+ acute lymphoblastic leukemia (ALL). This study aims to assess the safety and toxicity of CART-19 cells to patients who are refractory or at highest risk of relapse as defined by MRD+ status.

Interventions

BIOLOGICALCART-19

CART-19 cells treated

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

1 Years to 60 Years

Healthy volunteers

Inclusion criteria

* Signed written informed consent * Aged between 1-60 years * Patients with MRD positive CD19+ ALL * Cardiac: Left ventricular ejection fraction ≥ 50% * Adequate renal and hepatic function * Performance status: Karnofsky ≥ 70%

Exclusion criteria

* Pregnant or lactating females. * Any co-morbidity precluding the administration of CART-19 cells.

Design outcomes

Primary

Measure	Time frame
Leukemia free survival	1 year

Secondary

Measure	Time frame
Adverse events that are related to treatment	1 year

Countries

China

Contacts

Primary ContactJianda Hu, Prof.M.D.Ph.D

drjiandahu@163.com86-13959169016

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026